See more : MGC Ventures, Inc. (MGCV) Income Statement Analysis – Financial Results
Complete financial analysis of TTY Biopharm Company Limited (4105.TWO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of TTY Biopharm Company Limited, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Goodfood Market Corp. (GDDFF) Income Statement Analysis – Financial Results
- Chia Ta World Co., Ltd. (2033.TW) Income Statement Analysis – Financial Results
- Sanei Ltd. (6230.T) Income Statement Analysis – Financial Results
- Zhejiang Huahai Pharmaceutical Co., Ltd. (600521.SS) Income Statement Analysis – Financial Results
- Zhonghang Electronic Measuring Instruments Co.,Ltd (300114.SZ) Income Statement Analysis – Financial Results
TTY Biopharm Company Limited (4105.TWO)
About TTY Biopharm Company Limited
TTY Biopharm Company Limited, together with its subsidiaries, engages in the development and sale of pharmaceutical and chemical drugs in Taiwan and internationally. The company operates through Oncology Business Unit, Intensive Care Business Unit, Healthcare Business Unit, Export and CDMO Business Unit, and Other Business Unit segments. It offers oncology drugs under the Lipo-Dox, Lonsurf, UFUR, TS-1, Pexeda, Gemmis, Oxalip, Irino, Epicin, Tynen, Anazo, Folina, Thado, Andason, Ivic, Asadin, Leavdo, Painkyl, Megest, Episil, Otril, Zobonic, Yondelis, and Pemazyre names for anti-cancer and supplementary treatments. The company provides anti-infection drugs under the Brosym, Colimycin, Cubicin, Lipo-AB, Agrippal, Cepiro, Flusine, Maxtam, Metacin, and Flucelvax names for anti-infection and flu. In addition, it offers healthcare related drugs under the Algitab, Alginos, Alginos Fresh, Bio-Cal Plus, and Sulfin names for digest system, osteoporosis, and metabolism. Further, the company engages in the selling functional foods; and import and export trading and investment activities. The company was incorporated in 1960 and is headquartered in Taipei, Taiwan.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 5.51B | 5.06B | 4.54B | 4.22B | 4.46B |
| Cost of Revenue | 2.28B | 2.04B | 1.77B | 1.62B | 1.61B |
| Gross Profit | 3.22B | 3.02B | 2.77B | 2.60B | 2.86B |
| Gross Profit Ratio | 58.55% | 59.69% | 61.03% | 61.70% | 64.00% |
| Research & Development | 310.44M | 353.44M | 287.60M | 261.60M | 298.55M |
| General & Administrative | 425.42M | 413.31M | 402.99M | 404.76M | 0.00 |
| Selling & Marketing | 1.18B | 1.02B | 921.73M | 983.42M | 0.00 |
| SG&A | 1.60B | 1.44B | 1.32B | 1.39B | 1.33B |
| Other Expenses | 0.00 | 47.43M | -183.94M | 78.98M | 0.00 |
| Operating Expenses | 1.91B | 1.79B | 1.61B | 1.65B | 1.63B |
| Cost & Expenses | 4.13B | 3.83B | 3.38B | 3.27B | 3.23B |
| Interest Income | 80.20M | 31.17M | 6.31M | 14.98M | 40.45M |
| Interest Expense | 35.36M | 23.15M | 18.99M | 19.41M | 14.81M |
| Depreciation & Amortization | 200.90M | 186.28M | 167.28M | 157.00M | 151.32M |
| EBITDA | 1.66B | 1.50B | 1.14B | 1.38B | 1.42B |
| EBITDA Ratio | 30.07% | 31.87% | 28.23% | 32.42% | 31.73% |
| Operating Income | 1.37B | 1.43B | 1.11B | 1.21B | 1.23B |
| Operating Income Ratio | 24.93% | 28.19% | 24.54% | 28.70% | 27.56% |
| Total Other Income/Expenses | 47.03M | -134.94M | -68.28M | -173.17M | 19.87M |
| Income Before Tax | 1.42B | 1.41B | 1.09B | 1.20B | 1.25B |
| Income Before Tax Ratio | 25.78% | 27.82% | 23.97% | 28.46% | 28.01% |
| Income Tax Expense | 300.86M | 305.25M | 264.81M | 222.85M | 294.95M |
| Net Income | 1.13B | 1.09B | 831.89M | 924.18M | 900.08M |
| Net Income Ratio | 20.50% | 21.62% | 18.34% | 21.89% | 20.17% |
| EPS | 4.54 | 4.40 | 3.35 | 3.72 | 3.62 |
| EPS Diluted | 4.53 | 4.40 | 3.34 | 3.71 | 3.61 |
| Weighted Avg Shares Out | 248.65M | 248.65M | 248.65M | 248.65M | 248.65M |
| Weighted Avg Shares Out (Dil) | 249.08M | 249.01M | 249.06M | 249.06M | 249.00M |
Source: https://incomestatements.info
Category: Stock Reports